Evidence map›Paper›PMID 27196431›Full record

ArticlePLoS neglected tropical diseases2016

Programmatic Use of Molecular Xenomonitoring at the Level of Evaluation Units to Assess Persistence of Lymphatic Filariasis in Sri Lanka.

Ramakrishna U Rao, Sandhya D Samarasekera, Kumara C Nagodavithana, Manjula W Punchihewa, Tharanga D M Dassanayaka, Gamini P K D, Ethan Ford, Udaya S B Ranasinghe, Ralph H Henderson, Gary J Weil

Abstract readEvaluation Study
In one paragraph

Article in PLoS neglected tropical diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Evaluating the Diagnostic Test Accuracy of Molecular Xenomonitoring Methods for Characterizing Community Burden of Lymphatic Filariasis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. The use of molecular xenomonitoring for surveillance of mosquito-borne diseases.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2021
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ramakrishna U RaoDepartment of Internal Medicine, Infectious Diseases Division, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Sandhya D SamarasekeraAnti Filariasis Campaign, Sri Lanka Ministry of Health, Colombo, Sri Lanka.
Kumara C NagodavithanaAnti Filariasis Campaign, Sri Lanka Ministry of Health, Colombo, Sri Lanka.
Manjula W PunchihewaRegional Anti Filariasis Unit, Galle, Sri Lanka.
Tharanga D M DassanayakaAnti Filariasis Campaign, Sri Lanka Ministry of Health, Colombo, Sri Lanka.
Gamini P K DAnti Filariasis Campaign, Sri Lanka Ministry of Health, Colombo, Sri Lanka.
Ethan FordDepartment of Internal Medicine, Infectious Diseases Division, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Udaya S B RanasingheAnti Filariasis Campaign, Sri Lanka Ministry of Health, Colombo, Sri Lanka.
Ralph H HendersonTask Force for Global Heath and NTD Support Center, Atlanta, Georgia, United States of America.
Gary J WeilDepartment of Internal Medicine, Infectious Diseases Division, Washington University School of Medicine, St. Louis, Missouri, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSri Lanka's Anti Filariasis Campaign distributed 5 rounds of mass drug administration (MDA with DEC plus albendazole) to all endemic regions in the country from 2002-2006. Post-MDA surveillance results have generally been encouraging. However, recent studies have documented low level persistence of Wuchereria bancrofti in Galle district based on comprehensive surveys that include molecular xenomonitoring (MX, detection of filarial DNA in mosquitoes) results. The purposes of this study were to demonstrate the use of MX in large evaluation units (EUs) and to field test different mosquito sampling schemes. METHODOLOGY/PRINCIPAL

findingsGalle district (population 1.1 million) was divided into two EUs. These included a coastal EU with known persistent LF and an inland EU with little persistent LF. Mosquitoes were systematically sampled from ~300 trap locations in 30 randomly selected clusters (health administrative units) per EU. Approximately 28,000 Culex quinquefasciatus were collected with gravid traps and tested for filarial DNA by qPCR. 92/625 pools (14.7%) from the coastal EU and 8/583 pools (1.4%) from the inland EU were positive for filarial DNA. Maximum likelihood estimates (MLE) for filarial DNA rates were essentially the same when the same number of mosquito pools were collected and tested from 75, 150, or 300 trap sites (range 0.61-0.78% for the coastal EU and 0.04-0.07% for the inland EU). The ability to use a smaller number of trap sites reduces the cost and time required for mosquito sampling. CONCLUSIONS/SIGNIFICANCE: These results suggest there is widespread persistence of W. bancrofti infection in the coastal Galle EU 8 years after the last round of MDA in 2006, and this is consistent with other data from the district. This study has shown that MX can be used by national programs to assess and map the persistence of W. bancrofti at the level of large EUs in areas with Culex transmission.

Indexed as

AnimalsBloodCulexDNA, ProtozoanElephantiasis, FilarialFemaleHumansLikelihood FunctionsMosquito VectorsPrevalenceReal-Time Polymerase Chain ReactionSri LankaWuchereria bancroftiDNA, Protozoan

Identifiers

PMID27196431
PMCPMC4873130

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.